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Abstract
Aims: To update the themes of endoscopic and surgical treatment of Gastroesophageal Reﬂux
Disease (GERD) from the Mexican Consensus published in 2002.
Methods: Part I of the 2011 Consensus dealt with the general concepts, diagnosis, and medical
treatment of this disease. Part II covers the topics of the endoscopic and surgical treatment of
GERD. In this second part, an expert in endoscopy and an expert in GERD surgery, along with
the three general coordinators of the consensus, carried out an extensive bibliographic review
using the Embase, Cochrane, and Medline databases. Statements referring to the main aspects of
endoscopic and surgical treatment of this disease were elaborated and submitted to specialists
for their consideration and vote, utilizing the modiﬁed Delphi method. The statements were
accepted into the consensus if the level of agreement was 67% or higher.
Results: Twenty-ﬁve statements corresponding to the endoscopic and surgical treatment of
GERD resulted from the voting process, and they are presented herein as Part II of the consensus.
The majority of the statements had an average level of agreement approaching 90%.
Conclusions: Currently, endoscopic treatment of GERD should not be regarded as an option,
given that the clinical results at 3 and 5 years have not demonstrated durability or sustained
symptom remission. The surgical indications for GERD are well established; only those patients
meeting the full criteria should be candidates and their surgery should be performed by experts.
© 2012 Asociación Mexicana de Gastroenterología. Published by Masson Doyma México S.A. All
rights reserved.
 Please cite this article as: Huerta-Iga F, Tamayo-de la Cuesta J, Noble-Lugo A, et al. Consenso mexicano de enfermedad por relujo
gastroesofágico. Parte II. Revista de Gastroenterología de México. 2013;78:231--239.
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Consenso mexicano de enfermedad por relujo gastroesofágico. Parte II
Resumen
Objetivo: Actualizar los temas de tratamiento endoscópico y quirúrgico de la Enfermedad por
reﬂujo Gastroesofágico (ERGE) del Consenso Mexicano realizado en 2002.
Métodos: La primer parte de este consenso 2011 trató los conceptos generales, el diagnóstico
y el tratamiento médico de esta enfermedad. En esta segunda parte se abordan los temas del
tratamiento endoscópico y quirúrgico de la ERGE. En ella, un experto en endoscopía y un experto
en cirugía de la ERGE, así como los tres coordinadores generales del consenso, realizaron una
amplia revisión de la bibliografía utilizando las bases de datos Embase, Cochrane y Medline.
Se elaboraron enunciados referentes a los aspectos principales del tratamiento endoscópico y
quirúrgico de esta enfermedad y se sometieron a la consideración y votación de expertos en
estos temas mediante el método Delphi modiﬁcado. Los enunciados fueron aceptados cuando
alcanzaron el 67% o mas de consenso.
Resultados: Al ﬁnalizar todas las rondas de votación, se obtuvieron 25 enunciados, correspon-
dientes al tratamiento endoscópico y quirúrgico de la ERGE los cuales se presentan en esta
parte II del consenso. La mayor parte de ellos obtuvieron, en promedio, acuerdos cercanos al
90%.
Conclusion: En la actualidad, el tratamiento endoscópico de la ERGE no debe ser contemplado
como una opción debido a que los resultados a 3 y 5 an˜os no han demostrado durabilidad ni
la remisión sostenida de los síntomas. Las indicaciones del tratamiento quirúrgico están bien
establecidas y sólo se debe ofrecer esta opción a aquellos pacientes que sean buenos candidatos
y en manos de cirujanos expertos.
© 2012 Asociación Mexicana de Gastroenterología. Publicado por Masson Doyma México S.A.
Todos los derechos reservados.
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he aim of the 2011 Mexican Consensus on Gastroesopha-
eal Reﬂux Disease (GERD) was to update the 2002 Mexican
onsensus on GERD, based on new international scientiﬁc
vidence regarding this disease. For editorial purposes,
he consensus was divided into three parts: part I deals
ith epidemiology, pathophysiology, diagnosis, and medi-
al treatment; part II covers the endoscopic and surgical
anagement of GERD, and part III deals with GERD in the
ediatric population. The present article corresponds to part
I of the consensus.
ethods
he general coordinators selected six GERD experts as
oordinators for each of the tasks (deﬁnition and clinical
anifestations of GERD in adults, epidemiology and patho-
hysiology of GERD in adults, GERD diagnosis in adults,
edical treatment of GERD in adults, endoscopic and sur-
ical treatment of GERD in adults, and GERD in pediatrics).
he coordinators of each task carried out a thorough review
f the bibliography, using the Embase, Cochrane, and Med-
ine databases. After the review, each task coordinator
laborated a series of statements that covered the main
spects of the particular assigned topic.The proposed statements were electronically sent to the
oordinators of each of the working groups for a ﬁrst anony-
ous vote in which all the members of the 2011 GERD Study
roup panel participated. The only options for voting on
s
i
v
iach statement were «in agreement» or «in disagreement».
hen there was disagreement, the participants were asked
o give a written explanation of why they did not agree with
he statement. The results of this ﬁrst vote were registered,
nalyzed, and sent to each of the coordinators, together
ith the comments given by the participants. When agree-
ent with a statement was ≥ 75%, it was left unchanged to
o on to the next voting round. When disagreement with a
tatement was ≥ 75%, it was eliminated from the Consensus.
hen statements obtained less than 75% agreement or dis-
greement, the coordinator of each working group was asked
o rewrite the statement, taking into account the comments
ade by the participants, and to send the bibliography that
upported the proposed statement. This bibliography was
istributed to all the participants.
The second anonymous electronic vote included the
tatements that had more than 75% agreement in the ﬁrst
ote and those that had been rewritten as a result of the
omments made in the ﬁrst voting process. The methodol-
gy of this second vote was exactly the same as the one used
n the ﬁrst.
Once the feedback from the second anonymous voting
rocess was received, the coordinators elaborated a ﬁnal
ocument for each task in which every statement was indi-
idually upheld by bibliographic support. The document was
hen presented to the entire working group for a ﬁnal face-
o-face vote, maintaining anonymity by using electronic
oting systems. For this ﬁnal phase, the gastroenterologists
pecializing in adults voted on the statements correspond-
ng to tasks one through 5. In this ﬁnal voting process, the
otes were cast according to the following 6-point scale: A-
n complete agreement; B- in agreement, but with minor
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Level of agreement: A (in complete agreement) 45%; B (in
agreement but with minor concerns) 40%; C (in agreement
but with major concerns) 15%.The Mexican consensus on gastroesophageal reﬂux disease.
concerns; C- in agreement, but with major concerns; D- in
disagreement, but with major concerns; E- in disagreement,
but with minor concerns; or F- in complete disagreement.
Consensus was declared when 67% or more of the partici-
pants concurred on a category of agreement (A, B, or C).
The elaboration of the Mexican Consensus on Gas-
troesophageal Reﬂux Disease was funded by Laboratorio
Astra-Zeneca and had the academic backing of the Aso-
ciación Mexicana de Gastroenterología.
Results
In the ﬁnal vote, a total of 92 statements concerning adults
were discussed, 85 of which (92.4%) were accepted com-
pletely or with major or minor concerns. The percentages
for each statement are speciﬁed throughout the article. Part
II presents the statements that refer to the endoscopic and
surgical management of GERD.
V. The endoscopic and surgical treatment
of gastroesophageal reﬂux disease
68. Currently, the endoscopic treatment for GERD
should not be contemplated as an option due to
the fact that the long-term results (3 to 5 years)
have not shown durability or symptom remission
Level of agreement: A (in complete agreement) 100%.
69. In GERD complications, especially in Barrett’s
esophagus with high grade dysplasia (HGD),
ﬁrst-line endoscopic treatment is: endoscopic
mucosal resection and radiofrequency ablation,
which should be performed only in referral centers
and by highly qualiﬁed endoscopists
Level of agreement: A (in complete agreement) 100%.
70. Objective documentation of GERD is essential
before considering surgery
Level of agreement: A (in complete agreement) 100%.
Before contemplating surgery it is indispensable to have
objective documentation of GERD. This is obtained through
endoscopy that shows the damage to the mucosa presenting
as esophagitis, stricture,1 or Barrett’s esophagus. In the
absence of endoscopic evidence, 24-hr pH-metry is the study
of choice.2
71. All patients that are surgical candidates should
undergo preoperative endoscopy
Level of agreement: A (in complete agreement) 100%.
Endoscopy is the study every patient that is a candidate
for antireﬂux surgery should have. This study also aids in
making the diagnosis and enables the identiﬁcation of other
alterations.
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2. pH-metry is indicated in patients evaluated for
urgery that have no endoscopic evidence of
amage to the mucosa
evel of agreement: A (in complete agreement) 100%.
pH-metry is essential in patients in whom GERD diagnosis
annot be established through endoscopy.
3. An esophagram is occasionally indicated as a
reoperative study in order to have improved
natomic deﬁnition, especially in patients
ith hiatal hernia and short esophagus
evel of agreement: A (in complete agreement) 90%; B (in
greement but with minor concerns) 10%.
The barium esophagram is useful for having a more accu-
ately deﬁned anatomy, particularly in patients presenting
ith large hiatal hernias or short esophagus.
4. Preoperative manometry is useful for ruling
ut a motor disorder of the esophagus that
ontraindicates surgery (for example, achalasia).
ts inclusion in the preoperative evaluation is
ecommended, but there is no conclusive evidence
hat it needs to be carried out in all patients,
nd its application can be individualized
evel of agreement: A (in complete agreement) 75%; B (in
greement but with minor concerns) 25%; C (in agreement
ut with major concerns) 5%.
Many experts recommend ordering esophageal manome-
ry in all patients that are candidates for antireﬂux surgery.
owever, there is no conclusive evidence in the literature
upporting this as a measure for all patients.3--5
5. Surgical treatment can be considered
n patients with an objective diagnosis of GERD
nd some of the following:
Patients that choose surgical treatmment even though
they have a good response to medical management (due
to quality of life, prolonged use of medication, etc.)
Young patients or those with a life expectancy greater
than 10 years
Patients with uncontrolled regurgitation with acid sup-
pression
Patients with symptoms associated with non-acid reﬂux
Patients with a large hiatal hernia (>5 cm)
Patients with aspiration pneumoniaIn addition to the conditions mentioned, other indica-
ions for surgical treatment can include patients that have
xtraesophageal manifestations of GERD (asthma, snoring,
ough, chest pain).6--9 In this regard, it is recommended to
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onsider statements 87 and 88 of this consensus that are
resented further ahead.
GERD-associated complications such as stricture are also
ndications for anti-reﬂux surgery.10 In the case of Barrett’s
sophagus, surgical indication is clear when the patient has
ssociated symptoms such as heartburn and regurgitation.11
hen the patient is completely asymptomatic, the
ndication is more controversial. Up to the present, surgery
as not been shown to diminish the long-term risk for
ancer.12,13
6. Surgery should be offered to adequately
elected patients
evel of agreement: A (in complete agreement) 95%; B (in
greement but with minor concerns) 5%.
Adequately selected patients should be regarded as those
hat meet the criteria listed in statement 75 of this consen-
us.
7. Surgery is associated with good quality of life.
or this to hold true, surgery should be performed
ith minimal morbidity and in adequately selected
atients
evel of agreement: A (in complete agreement) 65%; B (in
greement but with minor concerns) 15%; C (in agreement
ut with major concerns) 10%, D (in disagreement but with
ajor concerns) 5%; F (in total disagreement) 5%.
Antireﬂux surgery has demonstrated an improvement in
uality of life similar to or greater than that of patients
hat receive medical treatment.14--18 In a recent Cochrane
ystematic review it was concluded that the short-term and
id-term quality of life is superior to that produced with
edical treatment.19
8. A standardized surgical technique has better
esults
evel of agreement: A (in complete agreement) 80%; B (in
greement but with minor concerns) 10%; D (in disagree-
ent but with major concerns) 5%; F (in total disagreement)
%.
Surgical technique standardization is advisable because
t has been shown to have good results.20
9. Surgery performed in high-volume centers
ith adequate selection and surgical technique has
etter resultsevel of agreement: A (in complete agreement) 100%.
The learning curve for antireﬂux surgery has been well
ocumented and shows that there are fewer complications
hen there is greater experience.21--23
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0. Laparoscopic surgery is the option of choice
nd should be preferred over open surgery due to
ts better early progression (shorter hospital stay,
arlier return to daily activities, and fewer
omplications) and the same long-term results
evel of agreement: A (in complete agreement) 95%; B (in
greement but with minor concerns) 5%.
Numerous studies show that there are signiﬁcantly fewer
omplications after laparoscopic surgery compared with
pen surgey and the long-term results are similar.24--42
1. Both total fundoplication and posterior partial
undoplication are effective in controlling reﬂux
evel of agreement: A (in complete agreement) 80%; B (in
greement but with minor concerns) 15%; C (in agreement
ut with major concerns) 5%.
Many studies have evaluated the differences between
otal and partial fundoplication. Signiﬁcant differences have
ot been shown with respect to the incidence of esophagi-
is, pyrosis, persistent acid reﬂux, or the Visick score.
here is signiﬁcantly more dysphagia, bloating, ﬂatulence,
nd reoperation rate after total fundoplication compared
ith the partial procedure.3,25,40,43--57 On the other hand, no
ifference in the progression of patients with esophageal
ysmotility has been demonstrated in relation to the type
f fundoplication.57,58
2. Robotic-assisted surgery is safe and effective
nd has a similar short-term progression, but a
igher cost, in the countries and centers in which
his technology is available
evel of agreement: A (in complete agreement) 90%; B (in
greement but with minor concerns) 10%.
The use of robotic-assisted surgery in antireﬂux surgery
as been shown to have similar results.59--64 However, the
ost is higher and surgery duration is longer with robotic
urgery.59,63,64
3. There is a higher incidence of failure in
ntireﬂux surgery in patients with morbid obesity
a BMI > 35 accompanied with comorbidities or a
MI > 40 with or without them) and gastric bypass
s a better antireﬂux surgery in these patients
ecause it also improves other diseases
evel of agreement: A (in complete agreement) 80%; B (in
greement but with minor concerns) 20%.
There are studies showing that antireﬂux surgery is less
ffective in patients with obesity compared with normal
eight individuals.65--68 However, other studies have shown
o differences between obese and non-obese patients.
aparoscopic gastric bypass is an extremely effective
urgery for resolving reﬂux. It also resolves numerous
omorbidities in patients with morbid obesity and there-
ore is recommended as an antireﬂux procedure in these
atients.69--76
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84. Age has not been demonstrated to signiﬁcantly
affect the results of antireﬂux surgery in well
selected patients that have adequate surgical risk
Level of agreement: A (in complete agreement) 60%; B (in
agreement but with minor concerns) 20%; C (in agreement
but with major concerns) 10%; D (in disagreement but with
major concerns) 5%; F (in total disagreement) 5%.
Age has not been shown to affect the results of antireﬂux
surgery.77
85. Patients with hiatal hernia > 3 cm have a
greater incidence of anatomic failure
Level of agreement: A (in complete agreement) 65%; B (in
agreement but with minor concerns) 30%; D (in disagree-
ment but with major concerns) 5%.
86. The patients with extraesophageal symptoms
have a poorer response to surgery compared
with those that have typical symptoms
Level of agreement: A (in complete agreement) 80%; B (in
agreement but with minor concerns) 20%.
Surgery in patients with atypical symptoms such as chest
pain, chronic cough, snoring, otitis media, recurrent pneu-
monia, and chronic bronchitis tends to be less effective than
in patients with typical symptoms.78,79
87. The patients presenting with extraesophageal
symptoms that have a better response to surgical
treatment are those whose symptoms are
correlated with episodes of reﬂux detected
through pH-metry or intraluminal impedence.
Surgery should not be considered in patients
with no symptom correlation in these studies
Level of agreement: A (in complete agreement) 95%; B (in
agreement but with minor concerns) 5%.
The correlation of symptoms with reﬂux episodes
detected through pH-metry or intraluminal impedence is
a predictor of a better response in patients with atypical
symptoms.80,81
88. Good response to preoperative medical
treatment is a predictor of good response
to surgery. Surgery should not be considered
in patients that do not have at least a partial
response to a PPI
Level of agreement: A (in complete agreement) 95%; B (in
agreement but with minor concerns) 5%.Symptom response to a proton pump inhibitor (PPI) is a
predictor of good response to antireﬂux surgery. However,
good results have also been demonstrated in patients with
GERD without such response or with a partial response.82
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9. Surgical reintervention is safe and effective
hen performed by surgeons with experience
n reoperation in high volume centers, but it is
ssociated with a longer surgery duration and a
igher complication rate than the primary
rocedure
evel of agreement: A (in complete agreement) 85%; B (in
greement but with minor concerns) 10%; D (in disagree-
ent but with major concerns) 5%.
Compared with the primary procedure, revision surgery
equires longer surgery duration, there is a higher
ercentage of conversion, and it has more
omplications.83--87 Nevertheless, patient satisfaction
as reached 89% with an elevated percentage of symptom
esolution.87--90
0. Antireﬂux surgery has been proved to be a safe
nd effective option for the treatment of GERD
evel of agreement: A (in complete agreement) 90%; C (in
greement but with major concerns) 10%.
Numerous controlled and randomized studies have shown
he effectiveness of antireﬂux surgery in patients with com-
lete PPI response, as well as in patients with partial
esponse.14--17,91--93 When manometry and pH-metry studies
re carried out, surgery results in signiﬁcantly less exposure
o acid and greater inferior esophageal sphincter pressure
ompared with medical treatment.14,15,18,94,95 In order for
urgery to compete with medical treatment, it must have a
inimum of morbidity and cost.
1. Antireﬂux surgery does not eliminate the need
or future surveillance in patients with Barrett’s
sophagus
evel of agreement: A (in complete agreement) 100%.
Surgery does not change the surveillance recommenda-
ions for patients with Barrett’s esophagus96--100 and it is not
he only therapeutic option for these patients.
2. Antireﬂux surgery has not been shown to
educe the long-term risk for cancer in patients
ith Barrett’s esophagus
evel of agreement: A (in complete agreement) 100%.
There is no evidence showing that antireﬂux surgery
educes the long-term risk for cancer.101
onclusions
resently, endoscopic treatment of GERD should not be
egarded as an option due to the fact that long-term results
3 to 5 years) have not shown durability or sustained symp-
om remission. The indications for surgical treatment are
ell established; this therapeutic option should be offered
o those patients that are good candidates and the surgery
hould be performed by experts.
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